Advances in Pharmacology

Cover

Contents

Chapter 1. Interactions between Drugs and Nutrients

I. Introduction

II. Factors Affecting Gastrointestinal Absorption

III. Bioavailability and Metabolism

IV. Excretion and Elimination

V. Special Interactions/Conditions

VI. Concluding Remarks

References

Chapter 2. Induction of Cyclo-Oxygenase and Nitric Oxide Synthase in Inflammation

I. General Introduction

II. Cyclo-Oxygenase

III. Regulation of COX-1 and COX-2

IV. Prostanoids

V. Future Developments

VI. COX-1 and COX-2 in Inflammation

VII. Pharmacological Inhibition of COX-1 and COX-2

VIII. Conclusion

IX. Nitric Oxide Synthase

X. Nitric Oxide in Mechanisms of Acute Inflammation

XI. Nitric Oxide in Mechanisms of Chronic Inflammation

XII. Nitric Oxide in Inflammatory Disease

XIII. Involvement of Nitric Oxide in Inflammatory Pain

XIV. Conclusion

XV. Interactions between the Nitric Oxide Synthase and Cyclo-Oxygenase Pathways

References

Chapter 3. Current and Future Therapeutic Approaches to Hyperlipidemia

I. Introduction

II. Agents That Predominantly Lower Cholesterol

III. Agents That Predominantly Lower Triglyceride

IV. Combination-Drug Therapy

V. Future Developments

VI. Conclusion

References

Chapter 4. In Vivo Pharmacological Effects of Ciclosporin and Some Analogues

I. Introduction and Summary

II. Molecular Mechanism of Immunosuppression

III. Suppressive Effects on Cell-Mediated Immunity

IV. Other Biological Effects Associated with the Immunosuppressive Activity

V. Biological Effects Possibly Correlated with the Immunosuppressive Activity

VI. Biological Effects Appearing Independently of Immunosuppressive Activity

VII. Chronic Allograft Rejection

VIII. Impact of Galenic Formulation on Pharmacokinetics

References

Chapter 5. Mono-ADP-ribosylation: A Reversible Posttranslational Modification of Proteins

I. Introduction

II. Mono-ADP-ribosyltransferases

III. Conserved Regions among ADP-ribosyltransferases

IV. ADP-ribosylarginine Hydrolases

V. Summary

References

Chapter 6. Activation of Programmed (Apoptotic) Cell Death for the Treatment of Prostate Cancer

I. Overview of the Problem

II. Androgen Sensitivity of Prostate Cancer

III. Cell Kinetics during Progression of Prostate Cancer

IV. Proliferation-Independent Therapeutic Approach for Androgen- Independent Proliferate Cancer Cells

V. Summary of the Temporal Sequences Involved in the Programmed Death of Normal Prostatic Glandular Cells Following Androgen Ablation

VI. Prostate Gene Expression during Programmed Cell Death Pathway Induced by Androgen Ablation

VII. Role of Cell Proliferation in the Prostatic Death Process Induced by Castration

VIII. Androgen Ablation Induced Programmed Cell Death Does not Require Recruitment into a Perturbed Cell Cycle

IX. p53 Expression Is not Required for Androgen Ablation-Induced Programmed Death of Go Prostatic Glandular Cells

X. Redefining the Prostate Cell CycleŽ

XI. Therapeutic Implication of Programmed Cell Death for Prostatic Cancer

XII. Ability of Thapsigargin (TG) to Activate Programmed Cell Death

XIII. Thapsigargin as Therapy for Prostate Cancer

References

Chapter 7. Reversal of Atherosclerosis with Therapy: Update of Coronary Angiographic Trials

I. Overview

II. Coronary Angiographic Trials Utilizing Pharmacological Intervention

III. Coronary Angiographic Trials Utilizing Nonpharmacological Intervention

IV. Summary of the Coronary Angiographic Trials

V. Conclusions from Coronary Angiographic Trials

References

Chapter 8. Unnatural Nucleotide Sequences in Biopharmaceutics

I. Introduction

II. Site-Specific Mutagenesis and Rational Drug Design

III. Molecular Evolution and Its Consequences

IV. Random Molecular and Chemical Libraries

V. Random Sequence Selection

VI. Applications of Random Sequence Selection

VII. Regulatory DNA Sequences and Binding Proteins

VIII. Production of Mutant Enzymes

IX. Gene Therapy for Human Cancer

X. Status, Summary, and Future Prospects

References

Chapter 9. Pharmacology of the Neurotransmitter Release Enhancer Linopirdine (DuP 996), and Insights into Its Mechanism of Action

I. Introduction

II. Pharmacology of Linopirdine

III. Mechanistic Studies on Linopirdine

Index